SCHEMBL32674374

SCHEMBL32674374

COc1ccc(Cn2c(=O)oc3ccc(CC(=O)O)c(F)c32)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMO O15229 1/20 0.45
▸ LMNA P02545 2/20 0.44
▸ CYP1A2 P05177 2/20 0.44
▸ CYP3A4 P08684 2/20 0.44
▸ CYP2C9 P11712 2/20 0.44
▸ TSHR P16473 2/20 0.44
▸ CYP2C19 P33261 2/20 0.44
▸ PMP22 Q01453 2/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ BLM P54132 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ ALDH1A1 P00352 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ RGS12 O14924 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ PKM P14618 1/20 0.43
▸ NFKB1 P19838 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ GNAI1 P63096 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32674120 0.90 MIF (0.41) KMOLMNATSHRALDH1A1KMT2A
SCHEMBL32674486 0.83 ALDH1A1 (0.41) KDM4EALDH1A1KMT2AMEN1MAPT
SCHEMBL32674300 0.77 PLA2G2A (0.42) TSHRKDM4EALDH1A1KMT2AMEN1
SCHEMBL32674502 0.76 MAPT (0.36) KDM4EALDH1A1KMT2AMEN1MAPT
SCHEMBL32674271 0.74 MAPT (0.47) KMOLMNAALDH1A1MAPTCD74
SCHEMBL32674408 0.72 LMNA (0.45) KMOLMNATSHRKDM4EALDH1A1
SCHEMBL31667649 0.71 KMT2A (0.48) LMNATSHRKDM4EALDH1A1KMT2A
SCHEMBL18805695 0.71 IDO1 (0.72) LMNATSHRALDH1A1KMT2ACD74
SCHEMBL16099478 0.71 POLB (0.51) KDM4ENPSR1ALDH1A1KMT2AMEN1
SCHEMBL32674496 0.70 KMT2A (0.44) LMNATSHRALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12565492-B2 Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof TRIANA BIOMEDICINES, INC. (US) 2026-03-03 — — US disclosed
US-20260042752-A1 ANAPLASTIC LYMPHOMA KINASE (ALK) DEGRADERS AND USES THEREOF TRIANA BIOMEDICINES INC (US) 2026-02-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260042752-A1 ANAPLASTIC LYMPHOMA KINASE (ALK) DEGRADERS AND USES THEREOF ALK, NTRK1, NTRK3 KMO 2986/4885LMNA 1027/4885CYP1A2 3287/4885
US-12565492-B2 Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof ALK, NTRK3, NTRK1 KMO 862/4885LMNA 1664/4885CYP1A2 3119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback